Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Magenta Therapeutics | 2021 | Post Ipo Equity | $86.4M | Cambridge |
| Theseus Pharmaceuticals | 2021 | Series B | $100.0M | New York |
| NewMed Medical | 2021 | Series C | $100.0M | Shanghai |
| Gemini Therapeutics | 2021 | Post Ipo Equity | $95.0M | Cambridge |
| Passage Bio | 2021 | Post Ipo Equity | $154.0M | Philadelphia |
| LogicBio Therapeutics | 2021 | Post Ipo Equity | Undisclosed | Foster City |
| EmendoBio, Inc. | 2020 | Corporate Round | $250.0M | New York |
| SAGE Therapeutics | 2020 | Post Ipo Equity | $650.0M | Cambridge |
| Turning Point Therapeutics | 2020 | Post Ipo Equity | $460.0M | San Diego |
| BioNova Pharma | 2020 | Series B | $25.0M | Shanghai |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 201 | Magenta Therapeutics | Post Ipo Equity | $86.4M | Cambridge, United States |
| 202 | Theseus Pharmaceuticals | Series B | $100.0M | New York, United States |
| 203 | NewMed Medical | Series C | $100.0M | Shanghai, China |
| 204 | Gemini Therapeutics | Post Ipo Equity | $95.0M | Cambridge, United States |
| 205 | Passage Bio | Post Ipo Equity | $154.0M | Philadelphia, United States |
| 206 | LogicBio Therapeutics | Post Ipo Equity | Undisclosed | Foster City, United States |
| 207 | EmendoBio, Inc. | Corporate Round | $250.0M | New York, United States |
| 208 | SAGE Therapeutics | Post Ipo Equity | $650.0M | Cambridge, United States |
| 209 | Turning Point Therapeutics | Post Ipo Equity | $460.0M | San Diego, United States |
| 210 | BioNova Pharma | Series B | $25.0M | Shanghai, China |
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
Theseus Pharmaceuticals is a technology-based company.
Medical device supplier based in Shanghai.
Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases.
Emendo is a biotechnology company
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.
BioNova Pharma biopharmaceutical company that develops treatments for cancer.
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.
BioShin is a clinical stage biopharmaceutical company.
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
MobileODT is an AI-based health-tech company that develops medical device technologies for cervical cancer screening.
PMV Pharmaceuticals is a developer of p53-targeted small molecule drugs for the treatment of cancer.
Perfuse Therapeutics specializes in developing therapies for the treatment of eye disease.
New Horizon Health is a bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes.
Pionyr Immunotherapeutics is a developer of cancer immunotherapies designed to target the tumor microenvironment.
Norson Biotechnology produces edible probiotic powders, fermented lactic acid bacteria beverages, and other products.
MabPlex provides CDMO services in the development and manufacturing of biopharmaceuticals.
Protekt Therapeutics is a drug development company aiming to develop inhibitors of PKR for various diseases
GrayBug is a biopharmaceutical company that develops transformative medicines for ocular diseases.
Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 21 different industry categories.
Among tracked funding rounds, SAGE Therapeutics received $650.0M in a Post Ipo Equity round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include Magenta Therapeutics, Theseus Pharmaceuticals, NewMed Medical, Gemini Therapeutics, Passage Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors